1 mg QD to 15 mg QD PF-06649751 + 3 mg QD to 15 mg QD PF-06649751 + 7 mg QD to 15 mg QD PF-06649751 + 15 mg QD PF-06649751 + 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) + 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) + 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) + 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Parkinson's Disease With Motor Fluctuations

Conditions

Parkinson's Disease With Motor Fluctuations

Trial Timeline

Jul 6, 2017 → Oct 25, 2017

NCT ID

NCT03185481

About 1 mg QD to 15 mg QD PF-06649751 + 3 mg QD to 15 mg QD PF-06649751 + 7 mg QD to 15 mg QD PF-06649751 + 15 mg QD PF-06649751 + 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) + 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) + 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) + 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD

1 mg QD to 15 mg QD PF-06649751 + 3 mg QD to 15 mg QD PF-06649751 + 7 mg QD to 15 mg QD PF-06649751 + 15 mg QD PF-06649751 + 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) + 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) + 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) + 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD is a phase 2 stage product being developed by Pfizer for Parkinson's Disease With Motor Fluctuations. The current trial status is terminated. This product is registered under clinical trial identifier NCT03185481. Target conditions include Parkinson's Disease With Motor Fluctuations.

What happened to similar drugs?

20 of 20 similar drugs in Parkinson's Disease With Motor Fluctuations were approved

Approved (20) Terminated (3) Active (0)

✅Lemborexant + placeboEisaiApproved

✅Levodopa-carbidopa intestinal gel (LCIG)AbbVieApproved

✅Carbidopa/levodopa/entacaponeNovartisApproved

✅Carbidopa/levodopa/entacapone + Immediate release carbidopa/levodopaNovartisApproved

✅carbidopa/levodopa + Carbidopa/Levodopa/EntacaponeNovartisApproved

✅carbidopa, levodopa, entacaponeNovartisApproved

✅Levodopa/carbidopa/entacapone + Levodopa/carbidopaNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03185481	Phase 2	Terminated	Jul 6, 2017	Oct 25, 2017	Parkinson's Disease With Motor Fluctuations

Competing Products

20 competing products in Parkinson's Disease With Motor Fluctuations

See all competitors

Product	Company	Stage	Hype Score
UB-312 + Placebo	Vaxxinity	Phase 1	19
NAV5001 + DaTscan	Navidea Biopharmaceuticals	Phase 3	22
piclozotan + 0.9% sodium chloride (normal saline)	Daiichi Sankyo	Phase 2	35
E2007	Eisai	Phase 3	32
ARICEPT	Eisai	Phase 3	40
Perampanel	Eisai	Phase 3	32
GPI 1485	Eisai	Phase 2	35
E2007	Eisai	Phase 3	40
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior Placebo	Eisai	Phase 3	40
perampanel + placebo	Eisai	Phase 2	27
Lemborexant + placebo	Eisai	Approved	50
Placebo + E2007 + E2007	Eisai	Phase 3	32
E2007 + E2007 + E2007	Eisai	Phase 2	35
E2007	Eisai	Phase 2	35
E2007	Eisai	Phase 2	27
E2007	Eisai	Phase 2	27
2 mg perampanel + 4 mg perampanel + placebo comparator	Eisai	Phase 3	40
Istradefylline (KW-6002)	Kyowa Kirin	Phase 2	35
Istradefylline 20 mg or 40 mg	Kyowa Kirin	Phase 3	40
Istradefylline (KW-6002)	Kyowa Kirin	Phase 3	40